However, effects on advanced fibrosis remain under investigation, with phase 2 trials of semaglutide showing MASH resolution without confirmed fibrosis improvement
Dosing Protocol Retatrutide was administered as a once-weekly subcutaneous injection with a carefully designed titration schedule to minimize side effects: Weeks 1-4: 2mg Weeks 5-8: 4mg Weeks 9-12: 6mg Weeks 13-16: 9mg (for 9mg group) or continue to 9mg (for 12mg group) Week 17+: 9mg maintenance (9mg group) or 12mg maintenance (12mg group) This gradual dose escalation over 12-16 weeks helped participants build tolerance to the medication's gastrointestinal effects while the therapeutic benefits accumulated
(PubMed) Zhao R, Min SH, Qiu A, et al
Acta Pharmaceutica (Zagreb, Croatia) (2012) 62(1):11522
Zoi Katsirma, Eirini Dimidi ORCID logo, Ana Rodriguez-Mateos ORCID logo and Kevin Whelan
Reporting this is not promotional